Cancer Screening for Longevity: The Evidence-Based Guide to What to Get and When
Cancer is the second leading cause of death in developed countries and one of the Four Horsemen of premature mortality. The longevity strategy for cancer is not primarily treatment — it is early detection, where most cancers are curable, and risk factor elimination, which prevents them from developing. This guide covers every major evidence-based cancer screening modality, including the emerging liquid biopsy technologies that may transform cancer detection.
- Early-stage cancer detection is associated with dramatically better survival across virtually every cancer type. Stage I colorectal cancer has a 5-year survival rate above 90 percent; Stage IV has 14 percent. Stage I lung cancer detected by CT screening has 5-year survival above 85 percent; Stage IV has under 10 percent. The mortality benefit of screening accrues almost entirely from stage shift — detecting cancer before it has metastasized.
- The US Preventive Services Task Force (USPSTF) A and B recommendations represent the highest standard of evidence-based cancer screening: low-dose CT lung cancer screening (annual, ages 50-80, 20+ pack-year smoking history), colonoscopy or stool-based colorectal cancer screening (ages 45-75), mammography for breast cancer (ages 40-74, biennial), and cervical cancer screening with Pap/HPV cotesting. PSA testing for prostate cancer remains a shared decision-making conversation.
- Multi-cancer early detection (MCED) liquid biopsy tests — which detect cell-free tumor DNA and protein biomarkers in blood — represent the most significant advance in cancer screening in decades. Grail's Galleri test, the most studied MCED test, detects a signal for 50+ cancer types from a single blood draw, with high specificity but currently limited sensitivity for early-stage cancers. It is not yet USPSTF-approved but is used in longevity medicine as an adjunct to standard screening.
- The USPSTF does not recommend PSA-based prostate cancer screening as a population-level recommendation (due to overdiagnosis and overtreatment concerns), but individualized PSA monitoring — particularly measuring PSA velocity (rate of change) and using MRI-guided biopsy when indicated — is a reasonable approach in men with longevity-oriented preventive care and awareness of the tradeoffs.
- Modifiable risk factor reduction is the highest-leverage cancer prevention strategy: tobacco cessation (reduces risk for 15 cancer types), maintaining healthy BMI and low visceral fat (elevated cancer risk mediator), alcohol minimization (Group 1 carcinogen for 7 cancer types), HPV vaccination in eligible individuals, and sun protection for melanoma.
The framing of cancer screening as a longevity intervention rather than merely a clinical screening recommendation changes how we think about its value and timing. The cancer that kills a 65-year-old was almost certainly seeded in their 40s or 50s. The cancer that kills a 75-year-old in 2040 is accumulating pathology today. The longevity strategy for cancer is detection before metastasis — when cure rates are high — and risk factor elimination that prevents cancers from forming.1
Evidence-Based Screening: USPSTF Grade A and B Recommendations
Colorectal cancer: The USPSTF recommends screening for all adults aged 45 to 75. Options include: colonoscopy every 10 years (the gold standard — detects and removes polyps before they become cancer); annual fecal immunochemical test (FIT) with colonoscopy if positive; or every 3-year stool DNA test (Cologuard). The NordICC trial (2022, NEJM) updated the evidence: colonoscopy invitation reduced colorectal cancer incidence by 18 percent and colorectal cancer mortality by 10 percent over 10 years in an intention-to-treat analysis. Per-protocol analysis in people who actually had colonoscopy showed larger effects.2
Lung cancer: Annual low-dose CT (LDCT) for current or former smokers aged 50 to 80 with a 20+ pack-year smoking history who currently smoke or quit within the past 15 years. The NLST trial found LDCT reduced lung cancer mortality by 20 percent compared to chest X-ray. Lung cancer has historically been diagnosed at late stages when cure is rarely possible; LDCT shifts detection to earlier, curable stages. Current smokers should receive cessation counseling alongside LDCT referral.
Breast cancer: Mammography every 2 years for women aged 40 to 74 (USPSTF 2024 recommendation, updated from 50). Women with BRCA1/2 mutations or strong family history warrant earlier initiation and potentially additional modalities (MRI). Dense breast tissue — present in approximately 40 percent of women — reduces mammography sensitivity; supplemental ultrasound or MRI may be warranted.3
Cervical cancer: Pap smear alone every 3 years (ages 21 to 65), or Pap plus HPV cotesting every 5 years (ages 30 to 65). HPV vaccination before sexual debut (approved through age 45) prevents approximately 90 percent of cervical cancers by eliminating the high-risk HPV strains that drive cervical carcinogenesis.
The PSA Conversation
PSA (prostate-specific antigen) testing for prostate cancer represents the most complex screening decision in longevity medicine. The USPSTF recommends individualized decision-making for men aged 55 to 69 after discussing benefits and harms — a downgrade from prior recommendations reflecting concerns about overdiagnosis (detecting slow-growing cancers that would never cause symptoms) and harms from overtreatment (erectile dysfunction and incontinence from unnecessary surgery or radiation).4
The longevity medicine approach to PSA is more nuanced: rather than a binary test/not-test decision, it involves establishing a baseline PSA in the early 40s, tracking PSA velocity (rate of change per year — above 0.75 ng/mL/year is concerning regardless of absolute level), using PSA density (PSA adjusted for prostate volume) to better stratify risk, and reserving biopsy for cases with rising PSA velocity or density thresholds using MRI guidance to target biopsy to suspicious lesions. This approach attempts to preserve the benefit of early detection while reducing the overdiagnosis and overtreatment that made PSA screening controversial.
Multi-Cancer Early Detection: The Emerging Frontier
Liquid biopsy multi-cancer early detection (MCED) tests analyze circulating tumor DNA (ctDNA) and protein biomarkers shed from cancer cells into the bloodstream, allowing detection of cancer signals before symptoms appear. Grail's Galleri test detects signals for over 50 cancer types from a single blood draw and predicts tissue of origin with approximately 89 percent accuracy when a signal is detected. In the PATHFINDER study, Galleri identified cancer signals in 1.4 percent of participants; approximately two-thirds of these were confirmed to have cancer on follow-up.5
Current limitations: sensitivity for early-stage (Stage I and II) cancers is still substantially lower than for late-stage cancers — the test is better at detecting cancers that are already advanced enough to shed abundant ctDNA. False positive rates are low (approximately 0.5 percent) but require follow-up workup. Cost ($950 list price) and lack of insurance coverage limit accessibility. Galleri is not currently USPSTF-approved but is used as an adjunct to standard screening in longevity medicine settings. The PATHFINDER 2 trial and NHS-Galleri trial are generating the population-level evidence needed for guideline consideration.
References
- 1Siegel RL, et al. "Cancer statistics, 2024." CA: A Cancer Journal for Clinicians. 2024;74(1):12-49. [PubMed]
- 2Bretthauer M, et al. "Effect of colonoscopy screening on risks of colorectal cancer and related death (NordICC)." NEJM. 2022;387(17):1547-1556. [PubMed]
- 3US Preventive Services Task Force. "Breast Cancer Screening." JAMA. 2024;331(22):1918-1930. [PubMed]
- 4US Preventive Services Task Force. "Screening for Prostate Cancer." JAMA. 2018;319(18):1901-1913. [PubMed]
- 5Schrag D, et al. "Blood-based tests for multicancer early detection (PATHFINDER)." NEJM. 2023;389(5):428-440. [PubMed]